Figure 2.
Impact of the presence of any somatic mutation on treatment outcomes after TKI therapy. Treatment outcomes include MMR, FFS, and OS. Results are shown for the overall population and imatinib-treated and 2G-TKI–treated groups.
Impact of the presence of any somatic mutation on treatment outcomes after TKI therapy. Treatment outcomes include MMR, FFS, and OS. Results are shown for the overall population and imatinib-treated and 2G-TKI–treated groups.
